$Galecto(GLTO.US) has been circulating in the M&A rumor mill for a while. Its fibrosis and oncology pipelines are high-quality targets for large pharma companies to supplement their pipelines, with AstraZeneca or Roche being the most frequently mentioned potential buyers. The acquisition premium range for similar biotech companies is 50-80%, the FDA pathway is relatively clear, and antitrust risks are low. Recently, there have been sporadic call-side movements but not in large volumes. Currently, the 90-day GEX is skewed negative, and short positions dominate, indicating that M&A expectations are far from being fully priced in. Once the rumors materialize, there is significant room for implied volatility compression, making the risk-reward structure of long-dated calls worth considering 📈